Chimerix Operating Income 2011-2024 | CMRX

Chimerix operating income from 2011 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Chimerix Operating Income 2011-2024 | CMRX

Chimerix operating income from 2011 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173.4B
Vertex Pharmaceuticals (VRTX)$119.5B
Regeneron Pharmaceuticals (REGN)$114.9B
Gilead Sciences (GILD)$104.1B
Bristol Myers Squibb (BMY)$103.2B
CSL (CSLLY)$95.9B
GSK (GSK)$84.4B
Alnylam Pharmaceuticals (ALNY)$35.3B
Argenex SE (ARGX)$32.1B
Biogen (BIIB)$28.4B
BioNTech SE (BNTX)$28.1B
Moderna (MRNA)$25.3B
BeiGene (BGNE)$21.2B
Illumina (ILMN)$20.7B
Genmab (GMAB)$16.1B
BioMarin Pharmaceutical (BMRN)$13.4B
Incyte (INCY)$12.7B
Vaxcyte (PCVX)$12.6B
Bio-Techne Corp (TECH)$12.5B
Insmed (INSM)$12.5B
Exact Sciences (EXAS)$12.2B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Legend Biotech (LEGN)$9B
Roivant Sciences (ROIV)$8.5B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8.2B
Intra-Cellular Therapies (ITCI)$7.7B
Exelixis (EXEL)$7.4B